Salk Institute
Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program From Salk Institute, Sanford Burnham Prebys
The company plans to begin clinical studies of ENV-201 in lung and colorectal cancers with LKB1 mutations within the next 18 months.
Salk Institute, BridgeBio Pharma Partner to Advance Precision Oncology Research
BridgeBio will fund research at the Salk Cancer Center over three years with the goal of developing new drugs based on the institute's research.